Fingolimod (FTY720) HCl is a 1-phospho-neuraminol S1P receptor antagonist with an IC50 of 0.33 nM. , FTY720 can dephosphorylate AMPK by activating PP2A and reduce the expression level of phosphorylated eEF2K, ultimately leading to ADCD and iron death in human multiple myeloma cells.
Eur J Pharmacol. 2022 Sep 15;931:175185.
Anemoside B4 ameliorates experimental autoimmune encephalomyelitis in mice by modulating inflammatory responses and the gut microbiota
FTY720 hydrochloride purchased from AbMole
Signal Transduct Target Ther. 2022 May 17;7(1):159.
Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants
FTY720 hydrochloride purchased from AbMole
Pulm Circ. 2020 Feb 10;10(1).
Sphingosine-1-phosphate Receptor-Independent Lung Endothelial Cell Barrier Disruption Induced by FTY720 Regioisomers
FTY720 hydrochloride purchased from AbMole
J Nat Prod. 2020 May 20.
Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models
FTY720 hydrochloride purchased from AbMole
Neuropharmacology. 2019 Nov 1;158:107701.
FTY720-Mitoxy reduces toxicity associated with MSA-like α-synuclein and oxidative stress by increasing trophic factor expression and myelin protein in OLN-93 oligodendroglia cell cultures.
FTY720 hydrochloride purchased from AbMole
Neuropharmacology. 2017 May 1;117:149-157.
FTY720 (Fingolimod) reverses a-synuclein-induced downregulation of brain-derived neurotrophic factor mRNA in OLN-93 oligodendroglial cells
FTY720 hydrochloride purchased from AbMole
Powder Diffraction. 2015;205-210.
Crystal structure of fingolimod hydrochloride, C19H34ClNO2
FTY720 hydrochloride purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | MCF-7 cells |
Preparation method | In Vitro Proliferation Assay Cells were seeded onto 96- well plates at the densities of 3000 cells/well. After 24 h of pre-cultivation, appropriate concentrations of the samples were added and the cells were cultured for 2 d. The relative growth ratio was determined by WST-1 assay using a cell counting kit (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer’s instructions. The IC50 value was determined from the dose response curve. At least three independent experiments were performed. The proliferation assay that tested the effects of DMS was performed using identical methods. Compounds with or without DMS were added to the wells and the plates were incubated for 78 h at 37 °C in a humidified atmosphere containing 5% CO2 before the WST-1 assay was conducted. |
Concentrations | 0~100µM |
Incubation time | 2 days |
Animal Experiment | |
---|---|
Animal models | Six-weekold female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice with Mino cells |
Formulation | not mentioned |
Dosages | 10 mg/kg daily for 10 days |
Administration | intraperitoneal injections |
Molecular Weight | 343.9 |
Formula | C19H33NO2.HCl |
CAS Number | 162359-56-0 |
Solubility (25°C) | DMSO 60 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] Cipriani R, et al. J Neuroinflammation. FTY720 attenuates excitotoxicity and neuroinflammation.
Related Src-bcr-Abl Products |
---|
Vodobatinib (K0706)
Vodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H , BCR-ABL1E255V and BCR-ABL1T315I, respectively. |
DGY-06-116
DGY-06-116 is an irreversible covalent and selective inhibitor of Src with IC50 of 2.6 nM. |
RK 24466
RK-24466 (KIN 001-51) is a potent and selective inhibitor of Lck that inhibits two constructs of the human lck kinase, lck (64-509) and lckcd with IC50 of < 0.001 μM and 0.002 μM, respectively. |
UM-164
UM-164 is a highly potent, dual c-Src/p38inhibitor of c-Src with a binding constant Kd of 2.7 nM for c-Src and inhibits both p38α and p38β. |
TP0427736 HCl
TP0427736 is a potent inhibitor of ALK5 kinase activity with an IC50 of 2.72 nM and this effect is 300-fold higher than the inhibitory effect on ALK3 (IC50 = 836 nM for ALK3). It also inhibits Smad2/3 phosphorylation in A549 cells induced by TGF-β1 with an IC50 value of 8.68 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.